Finn J. Hawkins

Finn J. Hawkins

Auto-generated profile, based on publicly available information

Finn J. Hawkins

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
TLTyler A. Longmire
Tyler A. Longmire
LILaertis Ikonomou
Laertis Ikonomou
FHFinn Hawkins
Finn Hawkins
CCConstantina Christodoulou
Constantina Christodoulou
YCYuxia Cao
Yuxia Cao
DKDarrell N. Kotton
Darrell N. Kotton

2 May 2017 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
FHFinn Hawkins
Finn Hawkins
PKPhilipp Kramer
Philipp Kramer
AJAnjali Jacob
Anjali Jacob
IDIan Driver
Ian Driver
DTDylan C. Thomas
Dylan C. Thomas
DKDarrell N. Kotton
Darrell N. Kotton
It has been postulated that during human fetal development, all cells of the lung epithelium derive from embryonic, endodermal, NK2 homeobox 1–expressing (NKX2-1+) precursor cells. However, this hypothesis has not been formally tested owing to an inability to purify or track these progenitors for detailed characterization. Here we have engineered and developmentally differentiated NKX2-1GFP reporter pluripotent stem cells (PSCs) in vitro to generate and isolate human primordial lung progenitors that express NKX2-1 but are initially devoid of differentiated lung lineage markers. After sorting to purity, these primordial lung progenitors exhibited lung epithelial maturation. In the absence of mesenchymal coculture support, this NKX2-1+ population was able to generate epithelial-only spheroids in defined 3D cultures. Alternatively, when recombined with fetal mouse lung mesenchyme, the cells recapitulated epithelial-mesenchymal developing lung interactions. We imaged these progenitors in real time and performed time-series global transcriptomic profiling and single-cell RNA sequencing as they moved through the earliest moments of lung lineage specification. The profiles indicated that evolutionarily conserved, stage-dependent gene signatures of early lung development are expressed in primordial human lung progenitors and revealed a CD47hiCD26lo cell surface phenotype that allows their prospective isolation from untargeted, patient-specific PSCs for further in vitro differentiation and future applications in regenerative medicine.

1 April 2010 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
FMFabien Maldonado
Fabien Maldonado
RCRodrigo Cartin-Ceba
Rodrigo Cartin-Ceba
FHFinn J. Hawkins
Finn J. Hawkins
JRJay Ryu
Jay Ryu

10 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAditya Mithal
Aditya Mithal
ACAmalia Capilla
Amalia Capilla
DHDar Heinze
Dar Heinze
ABAndrew Berical
Andrew Berical
CVCarlos Villacorta-Martin
Carlos Villacorta-Martin
GMGustavo Mostoslavsky
Gustavo Mostoslavsky
Efficient generation of human induced pluripotent stem cell (hiPSC)-derived human intestinal organoids (HIOs) would facilitate the development of in vitro models for a variety of diseases that affect the gastrointestinal tract, such as inflammatory bowel disease or Cystic Fibrosis. Here, we report a directed differentiation protocol for the generation of mesenchyme-free HIOs that can be primed towards more colonic or proximal intestinal lineages in serum-free defined conditions. Using aCDX2eGFPiPSC knock-in reporter line to track the emergence of hindgut progenitors, we follow the kinetics ofCDX2expression throughout directed differentiation, enabling the purification of intestinal progenitors and robust generation of mesenchyme-free organoids expressing characteristic markers of small intestinal or colonic epithelium. We employ HIOs generated in this way to measureCFTRfunction using cystic fibrosis patient-derived iPSC lines before and after correction of theCFTRmutation, demonstrating their future potential for disease modeling and therapeutic screening applications.

8 February 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ABAndrew Berical
Andrew Berical
RLRhianna E. Lee
Rhianna E. Lee
SRScott H. Randell
Scott H. Randell
FHFinn Hawkins
Finn Hawkins
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the life-limiting hereditary disease, cystic fibrosis (CF). Decreased or absent functional CFTR protein in airway epithelial cells leads to abnormally viscous mucus and impaired mucociliary transport, resulting in bacterial infections and inflammation causing progressive lung damage. There are more than 2000 known variants in the CFTR gene. A subset of CF individuals with specific CFTR mutations qualify for pharmacotherapies of variable efficacy. These drugs, termed CFTR modulators, address key defects in protein folding, trafficking, abundance, and function at the apical cell membrane resulting from specific CFTR mutations. However, some CFTR mutations result in little or no CFTR mRNA or protein expression for which a pharmaceutical strategy is more challenging and remote. One approach to rescue CFTR function in the airway epithelium is to replace cells that carry a mutant CFTR sequence with cells that express a normal copy of the gene. Cell-based therapy theoretically has the potential to serve as a one-time cure for CF lung disease regardless of the causative CFTR mutation. In this review, we explore major challenges and recent progress toward this ambitious goal. The ideal therapeutic cell would: (1) be autologous to avoid the complications of rejection and immune-suppression; (2) be safely modified to express functional CFTR; (3) be expandable ex vivo to generate sufficient cell quantities to restore CFTR function; and (4) have the capacity to engraft, proliferate and persist long-term in recipient airways without complications. Herein, we explore human bronchial epithelial cells (HBECs) and induced pluripotent stem cells (iPSCs) as candidate cell therapies for CF and explore the challenges facing their delivery to the human airway.

29 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAndrew Berical
Andrew Berical
RLRhianna E. Lee
Rhianna E. Lee
JLJunjie Lu
Junjie Lu
MBMary Lou Beermann
Mary Lou Beermann
JSJake A. Le Suer
Jake A. Le Suer
FHFinn J. Hawkins
Finn J. Hawkins
Cystic fibrosis is a monogenic lung disease caused by dysfunction of the cystic fibrosis transmembrane conductance regulator anion channel, resulting in significant morbidity and mortality. The progress in elucidating the role of CFTR using established animal and cell-based models led to the recent discovery of effective modulators for most individuals with CF. However, a subset of individuals with CF do not respond to these modulators and there is an urgent need to develop novel therapeutic strategies. In this study, we generate a panel of airway epithelial cells using induced pluripotent stem cells from individuals with common or rare CFTR variants representative of three distinct classes of CFTR dysfunction. To measure CFTR function we adapt two established in vitro assays for use in induced pluripotent stem cell-derived airway cells. In both a 3-D spheroid assay using forskolin-induced swelling as well as planar cultures composed of polarized mucociliary airway epithelial cells, we detect genotype-specific differences in CFTR baseline function and response to CFTR modulators. These results demonstrate the potential of the human induced pluripotent stem cell platform as a research tool to study CF and in particular accelerate therapeutic development for CF caused by rare variants.